TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02941653

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Potassium nitrate 2% gel
Description: * Teeth will be cleaned using rubber cups associated to pumice and water;~* Relative isolation with roller cotton will be done;~* Prior to each bleaching session, the patients will receive the potassium nitrate 2% desensitivity gel application on vestibular surface, for 10 minutes.~* Gingival dam will be performed using a fluid resin (Top Dam, FGM, Brazil)~* A 35% hydrogen peroxide based bleaching agent will be mixed and applied on the vestibular surface of teeth, remaining for 40 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Potassium oxalate 5% gel
Description: * Teeth will be cleaned using rubber cups associated to pumice and water~* Relative isolation with roller cotton will be done;~* Prior to each bleaching session, the patients will receive the potassium OXALATE 5%~* Gingival dam will be performed using a fluid resin (Top Dam, FGM, Brazil) desensitivity gel application on vestibular surface, for 10 minutes.~* A 35% hydrogen peroxide based bleaching agent will be mixed and applied on the vestibular surface of teeth, remaining for 40 minutes.
Study: NCT04216251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMR101
Description: AMR101-oral predetermined protocol dosage, daily for a minimum of 8 weeks and maximum of 12 weeks
Study: NCT01479933

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Vitamin D3 40 micrograms (1600 IU) per day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D 80
Description: Vitamin D3 80 micrograms (3200 IU) per day
Study: NCT03798678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaglenastat Hydrochloride
Description: Given PO
Study: NCT00694850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat (Adempas, BAY63-2521)
Description: BAY63-2521 will be up-titrated from 1,0 mg TID to 2,5 mg TID
Study: NCT03781323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX
Description: Patients treated on protocol will be treated with modified FOLFOX. Patients will receive 10 cycles of FOLFOX, administered every other week. FOLFOX will be given on day 1 of each cycle.~Patients will receive oxaliplatin 85 mg/m² IV over 120 minutes, leucovorin 400 mg/m² IV over 120 minutes, 5-FU 400 mg/m² IVP followed by 5-FU 2400 mg/m² infuse over 46 hours.
Study: NCT01233869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib
Description: Once daily oral dose of 200 mg of bosutinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib
Description: Once daily oral dose of 400 mg of bosutinib transitioned to 200 mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily oral dose of placebo
Study: NCT03258125

Intervention type: GENETIC
Intervention: real time PCR (rPCR)
Description: A villus tissue (2.5 cm \* 2.5 cm \* 2.5 cm) will be cut off immediately from the center of placenta, avoiding the area of infarction, bleeding or calcification. After being washed with normal saline, the tissue will be preserved in liquid nitro¬gen at once for subsequent detection of miR-452 and MMP-9 expression by real time PCR (r-PCR). During this procedure total RNA will be extracted including miR-452 and mRNA of MMP-9. Then by reverse transcriptase RNA will be converted into DNA which will be amplification during the PCR, i.e. in real-time, and not at its end, as in conventional PCR. Expression of miR-452 and MMP-9 will be estimated and correlated with each other.

Intervention type: GENETIC
Intervention: real time PCR (rPCR)
Description: A villus tissue (2.5 cm \* 2.5 cm \* 2.5 cm) will be cut off immediately from the center of placenta, avoiding the area of infarction, bleeding or calcification. After being washed with normal saline, the tissue will be preserved in liquid nitro¬gen at once for subsequent detection of miR-452 and MMP-9 expression by real time PCR (r-PCR). During this procedure total RNA will be extracted including miR-452 and mRNA of MMP-9. Then by reverse transcriptase RNA will be converted into DNA which will be amplification during the PCR, i.e. in real-time, and not at its end, as in conventional PCR. Expression of miR-452 and MMP-9 will be estimated and correlated with each other.
Study: NCT00650065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetirizine HCl Tablets 10 mg
Description: 10mg, single dose fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zyrtec® Tablets 10 mg
Description: 10mg, single dose fasting
Study: NCT04235023

Intervention type: OTHER
Group type: OTHER
Intervention: myeloid PTP1B expression analysis
Description: peripheral blood macrophage PTP1B expression

Intervention type: OTHER
Group type: OTHER
Intervention: myeloid PTP1B expression analysis
Description: peripheral blood macrophage PTP1B expression
Study: NCT02970734

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breathe
Description: Six web-based cognitive behavioural therapy sessions. Telephone and email support are also provided during the program.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resource Webpage
Description: Static webpage listing anxiety resources.
Study: NCT00467389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil, 5 mg daily
Description: This is a commercially available cholinesterase inhibitor that is approved for use in Alzheimer's disease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil, 5 mg daily
Description: This is a commercially available cholinesterase inhibitor that is approved for use in Alzheimer's disease.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral Placebo
Description: Inactive Comparator with Similar Appearance to Active Medication

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral Placebo
Description: Inactive Comparator with Similar Appearance to Active Medication
Study: NCT03352011

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Primary Care Brief Mindfulness Training
Description: Primary Care Brief Mindfulness Training consists of four 90-minute group classes that teach sitting meditation, body scan, moving meditation, gentle yoga, and group discussion on topics such as non-judging, patience, trust, non-striving, acceptance, and letting go.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PTSD Psychoeducational Class
Description: The PTSD Psychoeducational Class is designed to provide a supportive environment for learning about PTSD-related issues and to help Veterans determine what recovery strategies will be most helpful for them. Session themes include Civilian Readjustment and PTSD, Trust, Safety, and Healing and Treatment Strategies.
Study: NCT01338129

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin c
Description: 1000 mg of vitamin c for 45 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo pills
Study: NCT02790125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching BMS-986166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching BMS-986166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching BMS-986166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching BMS-986166
Study: NCT04357145

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Dosage Home Exercise Training
Description: By giving more exercise to the experimental group, exercise adherence, pain and functionality will be compared with the standard exercise group.~3 times more reputation than control~Exercise Program to be Applied (0-3 Weeks):~Isometric knee extensor and adductor exercise~* Hamstring stretching exercise~* Terminal knee extension exercise~* Straight leg lifting exercise~Exercise Program to be Applied (3-12 Weeks):~* Stepping exercise~* Sit up and stand up without support~* Active knee flexion exercise~* Moving forward exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Dosage Home Exercise Training
Description: 5-6 standard reputations for all exercises~Exercise Program to be Applied (0-3 Weeks):~Isometric knee extensor and adductor exercise~* Hamstring stretching exercise~* Terminal knee extension exercise~* Straight leg lifting exercise~Exercise Program to be Applied (3-12 Weeks):~* Stepping exercise~* Sit up and stand up without support~* Active knee flexion exercise~* Moving forward exercise
Study: NCT01775839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin+Clopidogrel/Digoxin(oral)
Description: oral administration of digoxin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin+Clopidogrel/Digoxin(IV)
Description: intravenous administration of digoxin
Study: NCT03508258

Intervention type: OTHER
Intervention: Non-interventional
Description: Non-interventional

Intervention type: OTHER
Intervention: Non-Interventional
Description: Non-Interventional
Study: NCT00533468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Cream 4%
Description: Topical cream, 2g applied under occlusive dressing for 20 minutes prior to the procedure

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: inactive placebo without LMX4
Study: NCT01187849

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Volunteers will be given Metformin or placebo for 1 month, once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Volunteers will be given Metformin or placebo for 1 month, once daily
Study: NCT01951781

Intervention type: OTHER
Group type: OTHER
Intervention: blood sample
Description: blood sample in newborn preterms suspected of nosocomial infection (neoCD64 arm)~When late-onset sepsis is suspected, blood samples are obtained from peripheral veins for a complete blood count, measurement of CRP and PCT concentration and one bacterial culture acording to the current recommendation of the CDC. CD64 concentration measurement require 0.2 ml aditionnal blood.
Study: NCT02650414

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cohort 1
Description: Subjects \<50kg will receive 0.2-1 x 10\^7 CART22 cells/kg as a split dose over three days as follows:~Day 1, 10% fraction: 0.2-1x10\^6 CART22 cells/kg Day 2, 30% fraction: 0.6-3x10\^6 CART22 cells/kg Day 3, 60% fraction: 1.2-6x10\^6 CART22 cells/kg~Subjects ≥50kg will receive 1-5x10\^8 CART22 cells as a split dose over three days as follows:~Day 1, 10% fraction: 1-5x10\^7 CART22 cells/kg Day 2, 30% fraction: 0.3-1.5x10\^8 CART22 cells/kg Day 3, 60% fraction: 0.6-3x10\^8 CART22 cells/kg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cohorts 2
Description: Subjects \<50kg will receive 0.2-1 x 10\^7 CART22-65s cells/kg as a split dose over three days as follows:~Day 1, 10% fraction: 0.2-1x10\^6 CART22-65s cells/kg Day 2, 30% fraction: 0.6-3x10\^6 CART22-65s cells/kg Day 3, 60% fraction: 1.2-6x10\^6 CART22-65s cells/kg~Subjects ≥50kg will receive 1-5x10\^8 CART22-65s cells as a split dose over three days as follows:~Day 1, 10% fraction: 1-5x10\^7 CART22-65s cells/kg Day 2, 30% fraction: 0.3-1.5x10\^8 CART22-65s cells/kg Day 3, 60% fraction: 0.6-3x10\^8 CART22-65s cells/kg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cohort 3
Description: Subjects \<50kg will receive 0.2-1 x 10\^7 CART22-65s cells as a split dose over two days as follows:~Day 1, 25% fraction: 0.5-2.5x10\^6 CAR T cells/kg Day 2, 75% fraction: 1.5-7.5x10\^6 CAR T cells/kg~Subjects ≥50kg will receive 1-5x10\^8 CART22-65s cells as a split dose over two days as follows:~Day 1, 25% fraction: 0.25-1.25x10\^8 CART22-65s cells Day 2, 75% fraction: 0.75-3.75x10\^8 CART22-65s cells
Study: NCT04112446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saroglitazar magnesium
Description: On Day 1, subjects will receive a single oral dose of \[14C\]-saroglitazar magnesium
Study: NCT03836820

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical pilates exercise
Description: Clinical pilates exercises will be performed three days in a week. Treatment will continue an hour in per session for 8 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical pilates exercise
Description: Clinical pilates exercises will be performed three days in a week. Treatment will continue an hour in per session for 8 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Progressive aerobic walking exercise will be performed three days in a week. Exercise intensity will be 50- 80% of maximal heart rate and exercises will be performed 45 minutes in per session for 8 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Progressive aerobic walking exercise will be performed three days in a week. Exercise intensity will be 50- 80% of maximal heart rate and exercises will be performed 45 minutes in per session for 8 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Pilates and Aerobic Exercise
Description: Both clinical pilates exercises and progressive aerobic walking exercises will be performed three days in a week for 8 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Pilates and Aerobic Exercise
Description: Both clinical pilates exercises and progressive aerobic walking exercises will be performed three days in a week for 8 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Pilates and Aerobic Exercise
Description: Both clinical pilates exercises and progressive aerobic walking exercises will be performed three days in a week for 8 weeks.
Study: NCT03255057

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemolung Respiratory Assist System
Description: Treatment with a medical device called the Hemolung RAS. The Hemolung RAS includes three components: the Hemolung Controller, the Hemolung Cartridge, and the Hemolung Catheter. The intervention is use of the Hemolung RAS to provide partial lung support for acute hypercapnic lung failure by filtering carbon dioxide from venous blood using a central venous catheter through which venous blood is pumped at flows of 350-550 milliliters per minute to and from an external circuit containing a hollow fiber membrane blood gas exchanger (with heparin-coated fibers) integrated with a centrifugal pump.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Invasive mechanical ventilation
Description: Lung support for acute lung failure applied with a mechanical ventilation device that uses positive pressure to mechanically inflate the lungs and facilitate exhalation via an endotracheal tube or tracheotomy.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Invasive mechanical ventilation
Description: Lung support for acute lung failure applied with a mechanical ventilation device that uses positive pressure to mechanically inflate the lungs and facilitate exhalation via an endotracheal tube or tracheotomy.
Study: NCT03356171

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiac Coherence
Description: * 10 sessions of HRV-BF (45mn) weekly over 12 weeks. HRV-BF is a cognitive behavioural therapy consisting on stress management training based on breathing. We use the SYMBIOLINE PC software to record the heart rate variability biofeedback, with an infrared plethysmograph sensor. The sensor is put on the finger, and the patient's HRV pattern is displayed in real time.~* 24 APA sessions (1.5h) bi-weekly over 12 weeks. Each session includes aerobic exercises (walk, step) and resistant exercises (muscular reinforcement). This program is built on previous cancer studies to make it effective.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adapted Physical Activity
Description: - 24 APA sessions (1.5h) bi-weekly over 12 weeks. Each session includes aerobic exercises (walk, step) and resistant exercises (muscular reinforcement). This program is built on previous cancer studies to make it effective.
Study: NCT02169817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bacillus clausii
Description: Pharmaceutical form:aqueous suspension Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Rehydration Therapy
Description: Pharmaceutical form:vials/sachets for solution Route of administration: oral
Study: NCT02320136

Intervention type: BEHAVIORAL
Intervention: cognitive testing
Description: patients perform simple tasks like watching a video or memorizing items

Intervention type: BEHAVIORAL
Intervention: cognitive testing
Description: patients perform simple tasks like watching a video or memorizing items

Intervention type: BEHAVIORAL
Intervention: cognitive testing
Description: patients perform simple tasks like watching a video or memorizing items
Study: NCT03518138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Q-122
Description: oral capsule of Q-122

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral capsule of placebo
Study: NCT02952040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1517
Description: Oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1517
Description: Oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate hydrate
Description: Oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate hydrate
Description: Oral dose
Study: NCT01839253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: b-blocker(Atenolol)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACE inhibitor(Enapril)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control
Study: NCT01756469

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Intervention for Alcohol Use
Description: Behavioral Intervention for Alcohol Use
Study: NCT00729781

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polyester Implants
Description: Three polyester (PET) implants will be implanted in each side of the nose affected by external NVC. See the detailed description for information about the implant procedure.
Study: NCT03426826

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: FMT versus placebo
Description: Biological/Vaccine: Fecal Microbial Transplant versus placebo Fecal Transplant via endoscopy.~Other Names:~FMT

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FMT versus placebo
Description: Biological/Vaccine: Fecal Microbial Transplant versus placebo Fecal Transplant via endoscopy.~Other Names:~FMT
Study: NCT03512691

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information on CVD Risk
Description: Respondents will be provided three types of information on CVD risks: a CVD base rate, a personalized CVD risk and an optimal CVD risk. The CVD base rate will be predicted from the respondent's age and sex only. After reporting their own chance of having a heart attack or stroke within ten years, the respondents in the treatment group will be told the risk for someone with the same age, sex, smoking status, body mass index (BMI) and blood pressure as them. Finally, a treatment group respondent will receive information on what the 10-year CVD risk would be for someone of the same age and gender who did not smoke, and had normal blood pressure and BMI.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lottery Incentive
Description: Respondents will simply be told that they can enter a lottery if they go to the specified clinic for a checkup. The health facilities will be told to conduct an assessment deemed appropriate for any particular patient that requests to be issued with a lottery ticket. No instructions will be given that the facilities should follow the PhilPEN protocol. We will evaluate whether they do implement the protocol for patients who qualify (by age if nothing else) for full risk screening.
Study: NCT02137122

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Stimulation
Description: Administer 30 seconds of 2 mA electrical current to the head through saline soaked electrodes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: Participants will undergo 20 minutes of 2 mA electrical stimulation to the head through saline soaked electrodes.
Study: NCT03514030

Intervention type: DIAGNOSTIC_TEST
Intervention: serum AQP4-antibody testing method
Description: there are different methods of testing serum AQP4-antibody

Intervention type: DIAGNOSTIC_TEST
Intervention: serum AQP4-antibody testing method
Description: there are different methods of testing serum AQP4-antibody
Study: NCT01606020

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sleep deprivation
Description: Overnight, the subjects stay in their homes (reading, watching TV, playing cards). Two experimenters will take turns to never leave them alone and avoid any micro-sleep.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sleep deprivation
Description: Overnight, the subjects stay in their homes (reading, watching TV, playing cards). Two experimenters will take turns to never leave them alone and avoid any micro-sleep.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No intervention
Description: Overnight, the subjects stay in their homes. No intervention during this night

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No intervention
Description: Overnight, the subjects stay in their homes. No intervention during this night
Study: NCT03579082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given ivgtt
Study: NCT04160052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given SC or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study: NCT00789750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colesevelam
Description: Colesevelam 625 mg tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets appearing to be colesevelam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: 30 mg or 45 mg pioglitazone therapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pioglitazone
Description: 30 mg or 45 mg pioglitazone therapy
Study: NCT02339064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apomorphine infusion
Description: Treatment with apomorphine provided by continuous subcutaneous infusion using a portable external electronic pump device